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characterized by loss of certain mental abilities. The loss is severe enough to interfere with normal activities and lasts at least six months. AD is not present at birth but usually develops during old age. It is marked by a decline in mental functions such as memory, reasoning, and the ability to plan. 1 The more basic pathological abnormalities in AD are amyloid plaques, neurofibrillary tangles, and neuronal death. 2 Disorders of some neurotransmitters, to various degrees, occur in AD patients, whose level of acetylcholine (ACh) is decreased. 3 In the past two decades, many attempts have been made to understand the molecular pathogenesis of AD, and to provide early diagnosis and therapeutic control. Cholinergic neurotransmission is the main target for effective treatment strategies. Acetylcholinesterase (AChE). the principal cholinesterase in the brain, causes hydrolysis of the endogenouse neurotransmitter Ach. 4 AChE inhibitors may ameliorate several symptoms of AD since a cholinergic deficit is characteristic of AD. Elevation of ACh leads to functional improvement of central cholinergic synapses, protection of neuronal degeneration, and modification of amyloid precursor protein and regional enhanced synthesis of neurotrophic molecules. 5 Among the various AChE inhibitors, galantamine and huperzine A, isolated from plant extracts, have been used to treat the early symptoms of AD. This suggests that novel acetylcholinesterase inhibitors from plant sources could be valuable alternatives in AD treatment. Salvia miltiorrhiza Bunge (Lamiaceae), a wellknown Chinese herbal plant, and its roots, known as Danshen in Chinese, are widely used for the treatment of menstrual disorders and blood circulation diseases, and for the prevention of inflammation. 6 The chief bioactive ingredients of S. miltiorrhiza roots are the diterpenoid pigments, particularly the phenanthrofurane quinone derivatives known as tanshinones. Hairy root culture of S. miltiorrhiza has been established as a potential means for tanshinone production. 7 Nitric oxide (NO) is a gaseous lipophilic free radical cellular messenger. It is synthesized from arginine by three distinct isoforms of nitric oxide synthases (NOS), neuronal (nNOS), inducible (iNOS) and endothelial NOS (eNOS). It plays a role in neurotransmission and neuromodulation. 8 However, overproduction of NO appears to be deleterious since it is associated with seizures and brain damage. On the other hand, the expression of NOS during development appears to be important for the final stages of neuronal differentiation. Although commonly localized to macrophage immune cells, iNOS is observed primarily in neurons and astrocytes in AD. 9 The footprint of NO's past presence includes observation of nitrated proteins in AD brains, compared with normal age-matched brains, suggesting that NO plays a role in the disease process. 10 In the present study, we investigate the influence of tanshinone on the levels of NOS and AChE in the brain of Alzheimer's disease rats to determine the potential therapeutic mechanism of tanshinone, to develop Alzheimer's disease therapeutics and to extend the use of Chinese Medicine all over the world.
Materials

Animals
Adult male Sprague-Dawley (SD) rats (n=100, 220~250g from the Experimental Animal Center of Chinese Second Military Medical University) were housed 6 per cage with free access to food and water, and kept in a constant environment (22 ± 2°C, 50 ± 5% humidity, 12h light/dark cycle). Experimental animals were overseen and approved by the Animal Care and Use Committee of Changzheng Hospital of Chinese Second Military Medical University before and during experiments.
Chemicals and reagents
Tanshinone was obtained from the National Institute for the standard substance of pharmaceutical and biological products, P.R. China. A Chemicals were of analytical reagent grade. Before the experiment, all vessels and tips for pipetting were dipped in strong HNO3 for 24 h and then washed with ultrapure water. The water used was purified in a Milli-Q water purification system (Millipore, Bedford, MA, USA).
Methods
Preparation of A 1-42-Infused Alzheimer's Disease Rat Model
A 1-42 was dissolved in sterile distilled water at a concentration of 5μg/μL, and incubated at 37°C for 7 days to obtain the aggregated form. Under anesthetization, 10 g (2μL) A 1-42 was injected bilaterally into the dorsal lateral of the dentate gyrus in the hippocampus of rats.
Groups
100 Male SD rats were divided into three groups: control group (30 rats), model group (35 rats) and tanshinone treatment group (35 rats). 24h after modeling, tanshinone, 50mg/kg, was administered by gastric perfusion to rats in the tanshinone treatment group, for 14 days, once per day. No medication was given in the model group and control groups.
Immunohistochemical assay
Animals were perfused through the heart under deep anaesthesia, chloral hydrate 0.35mL/100g, with 100mL PBS containing 10U/mL heparin followed by 150~200mL of paraformaldehyde 4% in PBS, pH=7.4. The brains were removed and immersed in PBS containing sucrose, pH=7.4, first at sucrose 20% for 24 h and then at 30% until sunk (2~5 days). Sections, 8μm, were cut on a cryostat and mounted in polylysine -coated slices. The number of nNOS and iNOS positive cells around the injection point was analyzed immunohistochemically using an antibody against nNOS, dilution 1:50, and antibody against iNOS,dilution 1:50. Positive immunohistochemistry controls were used. routinely Negative control sections were incubated with PBS instead of the primary antibody. Reproducibility of staining was confirmed by re-immunostaining ,using the same method, in multiple, randomly selected specimens. For visualization, under light microscopy, incubation with biotinylated rabbit/mouse anti-rat IgG and the immunoreaction was visualized using diaminobenzidine. Counting of nNOS and iNOS-expressing cells in subregions (CA1~ CA4) of each slides was done by an observer blind to the treatment status of the rats based on the visibility of a cell soma in 8μm-thick coronal sections in 400 fields by Olysia Bioreport software (Olympus company, Japan). Five slides around the injection point were evaluated per animal.
Western blot analysis
The hippocampus tissue was homogenized with an Ultra-Turrax homogenizer in 20mM Tris-Buffer (pH=7.4), containing 0.25 sucrose, EDTA (1mM), PMSF (100 g/mL), aprotinin (10 g/mL), leupeptin (10 g/mL) and soyabean trypsin inhibitor (10 g/mL). After centrifugation at 7800g for 10min, the supernatants were collected and kept at -70 until Western blot analysis was performed. The experiment was repeated three times. Protein (70 g) was loaded in each lane. Positive control aliquots were also loaded. We used mouse macrophage lysate for iNOS and rat pituitary lysate for nNOS. Samples were run on a 7.5% SDS-PAGE and transferred (overnight at 41 , voltages: 40V) to a nitrocellulose membrane. The blots were incubated with a rabbit antiserum against iNOS and nNOS for 2h at room temperature. All the primary antibodies were used at final dilutions 1: 1000 in the blocking buffer. The blots were washed with wash buffer (10mM Tris, 100mm NaCl, 0.1% v/v Tween-20, pH=7.5) followed by an alkaline phosphatase- 
Results
Expression of nNOS and iNOS
Injection of A 1-42 (10μg) in the hippocampus induced a decrease of nNOS and an increase of iNOS immunostaining (P<0.01), which were more significantly increased and decreased more in the tanshinonetreated rats, respectively (P<0.05) ( Figure 1A~C , 2A~C). Figure  1D, 2D) .
Western Blot analysis showed bands at 155 kDa and 130kDa corresponding to the size of nNOS and iNOS expressed at detectable levels in hippocampal homogenates of control animals. nNOS protein expression was reduced in the rats which had been injected by A 1-42. This was augmented by in vivo administration of tanshinone, but it did not increase nNOS expression above control levels ( Figure 3A) . iNOS protein expression was augmented by the administration of A 1-42. Administration of tanshinone attenuated the augmentation of iNOS expression due to A 1-42, but did not decrease iNOS expression under control levels ( Figure 3B ).
AChE positive fibers levels in hippocampus
AChE-positive neuron structures were found throughout the hippocampal formation of control brains. The positive nerve fibers, mostly of a varicose nature, formed a dense network with a laminar organization. Few positive cells were localized in the deepest portion of the granular layer in the dentate gyms. After administration of A 1-42, damage of AChE-positive nerve fibers appeared and the number decreased (P<0.01, Table 1 ); A very dense accumulation of positive nerve fibers was seen in each subregion (CA1~CA4) of hippocampus after rats being treated by tanshinone (P<0.05, Table 1 ). and aggregated forms of microtubule binding proteins. 13 AChE is the principal cholinesterase in the brain which causes hydrolysis of the endogenous neurotransmitter Ach. 14 AChE inhibitors are given for the treatment of AD because a cholinergic deficit is characteristic of AD and elevation of ACh levels leads to functional improvement of central cholinergic synapses. This protects neuronal degeneration, modifyies the amyloid precursor protein and enhances regional synthesis of neurotrophic molecules. Many plant extracts have been screened for activity against AChE. Galantamine and huperzine A have been introduced as drugs against the early symptoms of AD . [15] [16] It is likely that novel natural product AChE inhibitors exist, especially from traditional remedies for cognitive dysfunction. S. miltiorhiza contains diterpene quinines, known as tanshinone, which display several biological activities but there are no reports of anti-AD activity.
In the present study, we demonstrated that a single intracerebroventricular injection of A 1-42 induces a neuro-inflammatory response that is linked to a decline in learning and memory functions. In addition, by the use of Immumohistochemical Staining Assay and Western Blot Analysis, we have demonstrated a link between A 1-42, decrease of nNOS and increase of iNOS. Tanshinone might ameliorate the pathology of AD by increasing expression of nNOS and decreasing iNOS.
Nitric Oxide is an intra-and extra-cellular mediator of cell function. 17 Constitutive NOS isoforms, especially nNOS and iNOS, make up approximately 80% of NOS activity in the adult brain of rats. The production of NO by iNOS plays an important role in inflammation, host defence and tissue repair. Brain oxidative stress seems to exert an important role in cognitive impairment observed in AD. 18 iNOS generates NO and NO-derived reactive nitrogen species such as peroxynitrite. Accumulation of highly reactive molecules induces lipid peroxidation, tyrosine nitrosylation, DNA oxidative damage, and neuronal disruption, which are common characteristics of the AD brain. The inflammatory reaction induced by A in the CNS involves release of damaging factors, such as cytokines, NO and ROS that promote the activation of intracellular pathways, contributing to the progression of AD. [19] [20] Our results are in agreement with previous reports. The level of iNOS immunoreactivity and the number of iNOS positive neural cells in the hippocampus of A 1-42 injected rats increased. Western blot analysis showed an increase in the total expression of iNOS protein in hippocampus compared with controls. Moreover, there was a distinct loss of nNOS immunolabeled neurons in A 1-42 injected rats. Western blot analysis that the total expression of nNOS protein in the hippocampus decreased after A 1-42 hippocampal injection. Furthermore, in the present study, tanshinone increased the level of nNOS and decreased the level of iNOS which were induced by AD.
Since the recognition of the cholinergic deficit in AD, AChE has been widely investigated in tissues involved in the disease. A decrease in the ratio of G4/G1 molecular forms of AChE may appear in selected regions of the AD brain. 21 Most of the cortical AChE activity present in AD brain is associated with neuritic plaques, in which it is co-localized with A deposits. This includes both pre-amyloid diffuse deposits and mature senile plaques. Treatment with AChEI has generally been beneficial in ameliorating global cognitive dysfunction and, more specifically, it is most effective in improving attention. In this study, we observed changes in the level of AChE after A 1-42 and tanshinone administration by AChE histochemistry. 22 This allows, not only observation of detailed localization of AChE-containing structures with little background staining, but also simultaneous detection of neuron cell bodies and fibers. The technique is a modification of the direct thiocholine method of Karnovsky and Roots. Our results demonstrated that tanshinone, as an AChEI, could boost endogenous levels of AChE in the brain injected with A 1-42 and, thereby, enhance cholinergic neurotransmission.
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